{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"144"}],"units":"Participants"}],"description":"Number of participants who experienced grade 3 and higher AEs that were possibly, probably or definitely related to the vaccine.","groups":[{"description":"Gardasil (quadrivalent HPV types 6, 11, 16, 18) vaccination at weeks 0, 8, 24.\n\nquadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine\n\nlaboratory biomarker analysis","id":"OG000","title":"Vaccination"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The safety population included eligible participants who received at least one vaccination.","reportingStatus":"POSTED","timeFrame":"Through Month 24","title":"Occurrence of Grade ≥ 3 Adverse Events (AEs) That Were Possibly, Probably, or Definitely Related to the Vaccine","type":"SECONDARY","unitOfMeasure":"Participants"}